Current Report Filing (8-k)
07 September 2021 - 2:55PM
Edgar (US Regulatory)
0001322505
false
0001322505
2021-08-31
2021-08-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 31, 2021
ALBIREO PHARMA, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of
incorporation)
|
|
001-33451
(Commission File
Number)
|
|
90-0136863
(IRS Employer
Identification No.)
|
10 Post Office Square, Suite 1000
Boston, Massachusetts
(Address of principal executive offices)
|
|
02109
(Zip Code)
|
(857) 254-5555
Registrant’s telephone number, including
area code
Not applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
¨Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
|
Common Stock
|
|
ALBO
|
|
The Nasdaq Capital Market
|
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01. Entry Into a Material Definitive
Agreement
On
August 31, 2021, Albireo Pharma, Inc. and its subsidiary Albireo AB (collectively, “Albireo”) entered into a definitive
agreement (the “Agreement”) to sell a Priority Review Voucher relating to Albireo’s product BYLVAY (odevixibat) to Ares
Trading SA for cash proceeds of $105 million. The transaction remains subject to customary closing conditions, including the expiration
or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to
the transaction. A copy of Albireo’s press release announcing the Agreement is attached hereto as Exhibit 99.1.
The
foregoing summary of the Agreement is qualified in its entirety by the full text of the Agreement, a copy of which will be filed as an
exhibit, with certain portions potentially subject to confidential treatment, to Albireo's Quarterly Report on Form 10-Q for the quarter
ended September 30, 2021, and incorporated herein by reference.
Item 9.01. Financial Statements and
Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ALBIREO PHARMA, INC.
|
|
|
Date: September 7, 2021
|
/s/ Ronald H.W. Cooper
|
|
Ronald H.W. Cooper
|
|
President and Chief Executive Officer
|
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024